Ophthalmology Therapeutics Market: India and China to Lead Modest Growth: GBI Research

NEW YORK (GBI Research), 22 November 2013 -- The ophthalmology therapeutics market for Dry Eye Syndrome (DES) and glaucoma in four Asia-Pacific (APAC) countries — India, Australia, China and Japan — will increase from $2.4 billion in 2012 to $3.3 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%, forecasts business intelligence provider GBI Research.

The company’s latest report* states that the Indian market is expected to show the fastest growth over the forecast period, with almost a double-digit CAGR of 9.9%, followed by China with a CAGR of 5%.

In 2012, Japan had the largest share of the ophthalmology market with $1,065m (45%), followed by China, India and Australia with shares of $767m (33%), $427m (18%) and $95m (4%), respectively.

Saurabh Sharma, Senior Analyst for GBI Research, says: “Some of the major factors driving the market is the growing awareness of the importance of detecting ophthalmic diseases early, the availability of effective diagnostic tools, and an increase in the prevalence of both DES and glaucoma.”

Currently, there are five molecules in the Pre-registration stage of development that are expected to be granted approval within the forecast period. Two of these are indicated for DES and three for glaucoma.

Nearly 36% of the pipeline for glaucoma and DES are molecules in the late stages of development (Phases II and III), and of these, 21 molecules are indicated for DES and 28 are for glaucoma.

Sharma says: “The drug approval processes in many APAC countries, including Japan and China, require clinical trials to be run domestically in order to account for differences in drug metabolism between populations of different ethnicities. This can delay new drug launches, but in the long term it secures greater confidence in safety and efficacy profiles.”

However, many ophthalmic medications, such as Lumigan, are expected to lose patent exclusivity during the forecast period. GBI Research therefore expects the resulting increase in generic drug use to act as a barrier to the future growth of the ophthalmology therapeutics market.

*Ophthalmology Therapeutics Market in Asia-Pacific to 2019 – High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity



This report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES), in the Asia-Pacific (APAC) markets of India, China, Japan and Australia. It provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

-ABOUT GBI RESEARCH-

GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets. For more information, please contact our Press Office on +44 (0)1204 543 528 or at pr@gbiresearch.com.

Help employers find you! Check out all the jobs and post your resume.